RAPT_OUT_1 [2025-04-29 08:00:13 -0400] 5371 Bytes | 1500 tokens | Cum: 1500 tkns (18.75% of 8k)
==========================================================================

Lo, a marvel! RAPT Therapeutics (RAPT) ascendeth from $0.8786 to $0.9671 as the clock striketh 8:00 AM on Tue Apr 29, 2025. Shall we chart our course toward it, or deem it a spectre best left unseen?

--- COMPANY PROFILE ---
Company: RAPT Therapeutics (RAPT)
IPO: 2019-08-01 (5 Years Ago)
Market Cap: $117,472,876
Shares Outstanding: 132,009,999
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Here’s a list of headlines for RAPT Therapeutics:

Apr-15-25 08:00AM - RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
Mar-07-25 04:30PM - RAPT Therapeutics to Participate in Upcoming Investor Conferences
Mar-06-25 08:00AM - RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Feb-18-25 06:29AM - Hanmi Pharmaceuticals reports data from trial of Tivumecirnon for gastric cancer
Feb-10-25 12:00PM - All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy
Jan-09-25 08:00AM - RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan-06-25 08:00AM - RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors
Dec-27-24 06:10AM - Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
Dec-26-24 09:35AM - Progressive, EverQuote upgraded: Wall Street's top analyst calls
Dec-24-24 06:44AM - RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement
Dec-23-24 01:00PM - Why RAPT Therapeutics Stock Gained Over 100% On Monday?
Dec-23-24 01:00PM 07:10AM - RAPT Therapeutics Announces $150 Million Private Placement
Dec-23-24 01:00PM 07:00AM - RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
Nov-12-24 08:00AM - RAPT Therapeutics Reports Third Quarter 2024 Financial Results
Nov-11-24 12:18PM - RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull
Nov-11-24 12:18PM 08:00AM - Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
Sep-29-24 07:57AM - RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now
Sep-25-24 11:34AM - RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability
Aug-08-24 08:00AM - RAPT Therapeutics Reports Second Quarter 2024 Financial Results
Jun-21-24 01:13AM - Should You Sell Your Stake in RAPT Therapeutics (RAPT)?
Jun-14-24 09:35AM - Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround
May-29-24 09:35AM - Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-01-06T13:00:00Z - RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
B2 - 2024-07-19T14:00:27Z - Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data - Zacks Investment Research
B3 - 2024-07-17T14:01:28Z - Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why - Zacks Investment Research
B4 - 2024-07-16T14:30:42Z - Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why - Zacks Investment Research
B5 - 2024-07-10T13:01:37Z - Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment Research
B6 - 2024-07-02T16:12:00Z - SpringWorks (SWTX) Completes NDA Submission for Mirdametinib

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for RAPT Therapeutics (RAPT).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

RAPT_OUT_3 [2025-04-29 08:00:14 -0400] 975 Bytes | 283 tokens | Cum: 1785 tkns (22.31% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T08:18:27Z - Rising Awareness And Early Diagnosis Driving The Growth Of The Market Due To Improving Screening And...
A2 - 2025-04-18T17:27:17Z - RAPT Therapeutics, Inc. (NASDAQ:RAPT) Short Interest Update...
A3 - 2025-04-17T14:30:08Z - RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com...
A4 - 2025-04-17T11:52:56Z - Affinity Asset Advisors LLC Makes New $1.58 Million Investment in RAPT Therapeutics, Inc. (NASDAQ:RA...
A5 - 2025-04-15T05:26:48Z - RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of "Hold" from Brokerages...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RAPT_OUT_5 [2025-04-29 08:00:16 -0400] 1182 Bytes | 300 tokens | Cum: 2087 tkns (26.09% of 8k)
==========================================================================

Showing A1 (chunk 1 of 10): A1:
**Rising Awareness And Early Diagnosis Driving The Growth Of The Market Due To Improving Screening And Advanced Diagnostic Technologies: A Critical Driver Enhancing the PD-1 Resistant Head And Neck Cancer Market in 2025**Date: 2025-04-28Source: {'uri': 'whatech.com', 'dataType': 'news', 'title': 'WhaTech'}URL: https://whatech.com/og/markets-research/medical/952638-rising-awareness-and-early-diagnosis-driving-the-growth-of-the-market-due-to-improving-screening-and-advanced-diagnostic-technologies-a-critical-driver-enhancing-the-pd-1-resistant-head-and-neck-cancer-market-in-2025.html2025 Market Reports Update: Forecasts Through 2034, Emerging Trends, Key Players, and Leading Regions - Stay Ahead of the Competition Today!

The pd-1 resistant head and neck cancer by The Business Research Company provides a comprehensive analysis of the industry, covering market size forecasts from 2025 t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_7 [2025-04-29 08:00:17 -0400] 1182 Bytes | 267 tokens | Cum: 2356 tkns (29.45% of 8k)
==========================================================================

Showing A1 (chunk 2 of 10): o 2034. The report explores key trends shaping the market, major growth drivers, and detailed segmentation based on [key segment categories].

It also highlights the competitive landscape, profiling major companies operating in the industry.

How Has the PD-1 Resistant Head And Neck Cancer Market Grown in Recent Years?

In recent times, the market for PD-1 resistant head and neck cancer has expanded dramatically. It is projected to escalate from $1.28 billion in 2024 to $1.43 billion in 2025, experiencing a compound annual growth rate (CAGR) of 11.7%.

The historically observed growth is attributed to several factors including a higher prevalence, a growing preference for immunotherapy treatments, a spike in clinical trial activities, an increase in resistance to PD-1 inhibitors, and a heightened focus on combination therapies.

Download Your Free PD-1 Resistant Head And Neck Cancer Mark

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_9 [2025-04-29 08:00:18 -0400] 1182 Bytes | 260 tokens | Cum: 2618 tkns (32.73% of 8k)
==========================================================================

Showing A1 (chunk 3 of 10): et Report Sample Now:

www.thebusinessresearchcompany.com/sample....p;type=smp

What Is the Future Market Size of the PD-1 Resistant Head And Neck Cancer Industry?

Anticipations indicate a swift expansion in the market size for PD-1 resistant head and neck cancer in the ensuing years. By 2029, this market is slated to reach $2.20 billion, with a compound annual growth rate (CAGR) of 11.4%.

The expected growth over this projection period is due to several factors including a surge in biomarker research, increased innovation in creating new treatments, a growing interest in tailored healthcare strategies, escalating investments in research and development for oncology, and a rise in regulatory sanctions. Key market trends projected in this period encompass advanced combined treatments, progress in precision-focused oncology, the usage of next-generation sequencing, sophisticated research

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_11 [2025-04-29 08:00:19 -0400] 1182 Bytes | 249 tokens | Cum: 2869 tkns (35.86% of 8k)
==========================================================================

Showing A1 (chunk 4 of 10): on tumor microenvironments, and the incorporation of AI in drug discovery.

Access The Full Report Today!

www.thebusinessresearchcompany.com/purchas...x?id=22092

What Key Factors Are Driving the Growth of the PD-1 Resistant Head And Neck Cancer Market?

The surge in understanding and early identification is predicted to boost the PD-1-resistant head and neck cancer market's development. Enhanced screening programs, healthcare initiatives, and diagnostic technology advancements facilitate the growth in awareness and early detection of cancer, leading to prompt intervention and treatment.

Quick identification of PD-1-resistant head and neck cancer allows for immediate implementation of alternative therapies, enhancing treatment results and patient survival rates. As per the data provided by The National Health Service (NHS), a UK government department, in January 2025, quick cancer reg

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_13 [2025-04-29 08:00:20 -0400] 1182 Bytes | 293 tokens | Cum: 3164 tkns (39.55% of 8k)
==========================================================================

Showing A1 (chunk 5 of 10): istration data shows that 120,958 out of 206,038 commonplace cancers (58.7%) diagnosed from September 2023 to August 2024 were identified in the early stages, showing an increase of 2.7 percentage points in comparison to pre-pandemic levels, amounting to an additional estimated early diagnosis of 7,000 patients.

Hence, the escalating awareness and early detection serve as key factors influencing the growth of the PD-1-resistant head and neck cancer market.

Looking for something specific? Request customization here -

www.thebusinessresearchcompany.com/customi...p;type=smp

Which Key Players Are Leading the PD-1 Resistant Head And Neck Cancer Market?

Major companies operating in the PD-1 resistant head and neck cancer market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GSK plc, Amgen Inc., Boehringer Ingelheim Internat

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_15 [2025-04-29 08:00:20 -0400] 1182 Bytes | 315 tokens | Cum: 3481 tkns (43.51% of 8k)
==========================================================================

Showing A1 (chunk 6 of 10): ional GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, Coherus BioSciences Inc., Akeso Biopharma, Rakuten Medical Inc., PDS Biotechnology Corporation, LARVOL, Nanobiotix, ALX Oncology Holdings Inc., RAPT Therapeutics Inc., Immutep Limited.

What Are the Key Segments in the PD-1 Resistant Head And Neck Cancer Market?

The PD-1 resistant head and neck cancer market covered in this report is segmented -

1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy

2) By Stage Of Cancer: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Application: Squamous Cell Carcinoma, Adenocarcinoma, Nasopharyngeal Carcinoma, Throat Cancer

4) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Chemotherapy: Platinum-Based Chemotherapy, Taxanes, Antimetabolites, Topoisomerase Inhibitors

2) By Radiation Therapy: Intensity-Modulated Radi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_17 [2025-04-29 08:00:21 -0400] 1182 Bytes | 284 tokens | Cum: 3767 tkns (47.09% of 8k)
==========================================================================

Showing A1 (chunk 7 of 10): ation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Beam Therapy, Brachytherapy

3) By Surgery: Tumor Resection, Neck Dissection, Reconstructive Surgery, Laser Surgery

4) By Targeted Therapy: EGFR Inhibitors, Angiogenesis Inhibitors, Cyclin-Dependent Kinase Inhibitors, PI3K/AKT/mTOR Inhibitors

Maximize Your Market Potential - Get The Complete Report Now!

www.thebusinessresearchcompany.com/report/...ket-report

Which Key Trends Are Expected to Drive Innovation in the PD-1 Resistant Head And Neck Cancer Market During the Forecast Period?

The main players in the PD-1 resistant head and neck cancer market are focusing on high-tech innovations, such as tailored cancer therapies, in an effort to increase effectiveness and address resistance. Tailored cancer care adjusts treatment plans according to a patient's genetic makeup, tumor properties, and immunological respons

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_19 [2025-04-29 08:00:22 -0400] 1182 Bytes | 267 tokens | Cum: 4036 tkns (50.45% of 8k)
==========================================================================

Showing A1 (chunk 8 of 10): e, facilitating more precise and successful treatment.

As an illustration, in November 2024, the CEL-SCI Corporation, an American biotech firm, obtained FDA authorization for employing the PD-L1 biomarker in a study on head and neck cancer. Planned to commence in early 2025, the trial will concentrate on newly identified patients with low PD-L1 levels and zero lymph node involvement, in order to examine the safety and efficacy of Multikine (Leukocyte Interleukin, Injection).

Following an encouraging outcome from prior Phase 3 research, this study marks a considerable progression in personalized cancer therapy, providing renewed optimism for more effective management of PD1-resistant cancers.

Which Regions Are Experiencing the Fastest Growth in the PD-1 Resistant Head And Neck Cancer Market?

North America was the largest region in the PD-1 resistant head and neck cancer market 2024. T

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_21 [2025-04-29 08:00:23 -0400] 1182 Bytes | 261 tokens | Cum: 4299 tkns (53.74% of 8k)
==========================================================================

Showing A1 (chunk 9 of 10): he regions covered in the PD-1 resistant head and neck cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Questions Addressed In This Report:

1.What is the revenue and growth projection for the pd-1 resistant head and neck cancer market?

2.What factors are driving pd-1 resistant head and neck cancer market growth, globally?

3.Which segment accounted for the largest pd-1 resistant head and neck cancer market share?

4.Who are the top companies operating in the pd-1 resistant head and neck cancer market?

5.Which region is projected to witness the fastest growth during the forecast period?

News From

The Business Research Company ...

Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market repo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_23 [2025-04-29 08:00:24 -0400] 1043 Bytes | 233 tokens | Cum: 4534 tkns (56.67% of 8k)
==========================================================================

Showing A1 (chunk 10 of 10): rts across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark ...

This email address is being protected from spambots. You need JavaScript enabled to view it.

For more information:

www.thebusinessresearchcompany.com/report/...ket-report www.thebusinessresearchcompany.com/sample....p;type=smp www.thebusinessresearchcompany.com/purchas...x?id=22092 www.thebusinessresearchcompany.com/customi...p;type=smp in.linkedin.com/company...ch-company

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_25 [2025-04-29 08:00:25 -0400] 1110 Bytes | 277 tokens | Cum: 4813 tkns (60.16% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S3 - 2025-03-06 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing else...

S4 - 2025-03-06 8-K Item 2.02 Results of Oper and Fin Cond.

On March 6, 2025, RAPT Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to...

S9 - 2025-01-13 8-K Item 7.01 Regulation FD Disclosure.

RAPT Therapeutics, Inc. (the Company) is filing the investor presentation slides (the Corporate Presentation) attached hereto as Exhibit 99.1, which the Company may use from time to time in conversations with investors and analysts.

The inf...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RAPT_OUT_27 [2025-04-29 08:00:27 -0400] 1181 Bytes | 240 tokens | Cum: 5055 tkns (63.19% of 8k)
==========================================================================

Showing S3 (chunk 1 of 6): S3:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those discussed in the section titled Risk Factors included under Part I, Item 1A and elsewhere in this Annual Report. See Special Note Regarding Forward-Looking Statements in this Annual Report.

Overview

We are a clinical-stage immunology-based biopharmaceutical company

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_29 [2025-04-29 08:00:28 -0400] 1181 Bytes | 280 tokens | Cum: 5337 tkns (66.71% of 8k)
==========================================================================

Showing S3 (chunk 2 of 6): focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Our lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), a key driver of several allergic diseases.

In December 2024, we entered into an exclusive license agreement (the Jemincare License Agreement) with Shanghai Jemincare Pharmaceutical Co., Ltd (Jemincare), a subsidiary of Jiangxi Jemincare Group Co., Ltd., under which we have exclusive rights to develop and commercialize RPT904 worldwide, excluding mainland China, Hong Kong, Macau and Taiwan (together, the Jemincare Territory). We believe RPT904 could offer patients a potentially improved therapeutic option compared to omalizumab (Xolair ), an anti-IgE antibody approved for asthma, chronic spontaneous urticaria (CSU), chro

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_31 [2025-04-29 08:00:28 -0400] 1181 Bytes | 296 tokens | Cum: 5635 tkns (70.44% of 8k)
==========================================================================

Showing S3 (chunk 3 of 6): nic rhinosinusitis with nasal polyps and food allergy. In a Phase 1 clinical trial conducted by Jemincare comparing RPT904 and omalizumab, the median half-life of RPT904 was more than two times that of omalizumab at the same dose, and RPT904 demonstrated deeper and more sustained reduction of free IgE and higher total IgE accumulation compared to omalizumab at the same dose. We plan to pursue clinical development of RPT904 initially in food allergy and CSU.

Our oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (T reg ) into tumors. Data from a Phase 2 trial of patients with advanced checkpoint-nave non-small cell lung cancer (NSCLC) treated with tivumecirnon in combination with the checkpoint inhibitor pembrolizumab showed greater confirm

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_33 [2025-04-29 08:00:29 -0400] 1181 Bytes | 285 tokens | Cum: 5922 tkns (74.02% of 8k)
==========================================================================

Showing S3 (chunk 4 of 6): ed objective response rate and progression free survival than what has historically been demonstrated by pembrolizumab monotherapy. We hold worldwide rights to tivumecirnon, with the exception of the exclusive license (the Hanmi License Agreement) granted to Hanmi Pharmaceutical Ltd. (Hanmi) in Korea, mainland China, Hong Kong, Macau and Taiwan (together, the Hanmi Territory).

Zelnecirnon, our small molecule CCR4 antagonist for inflammatory disease, was being evaluated in two randomized, placebo-controlled Phase 2 clinical trials in asthma and atopic dermatitis (AD). Both trials were placed on clinical hold by the U.S. Food and Drug Administration (FDA) in February 2024 due to a serious adverse event (SAE) of liver failure in one patient in the AD trial, and we subsequently closed both trials. In November 2024, based on feedback from the FDA, we ceased development of zelnecirnon. We ar

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_35 [2025-04-29 08:00:30 -0400] 1181 Bytes | 263 tokens | Cum: 6187 tkns (77.34% of 8k)
==========================================================================

Showing S3 (chunk 5 of 6): e currently pursuing different novel CCR4 antagonists that we believe may have improved safety margins.

Financial Overview

Since commencing operations in 2015, we have devoted substantially all of our efforts and financial resources to building our research and development capabilities and establishing our corporate infrastructure. As a result, we have incurred net losses since inception. As of December 31, 2024, we had an accumulated deficit of $614.5 million. We have incurred net losses of $129.9 million and $116.8 million for the years ended December 31, 2024 and 2023, respectively. We do not expect to generate product revenue unless and until we obtain approval for the commercialization of a drug candidate, and we cannot assure you that we will ever generate significant product revenue or profits.

Since inception, we have financed our operations primarily through the sale of eq

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_37 [2025-04-29 08:00:30 -0400] 790 Bytes | 200 tokens | Cum: 6389 tkns (79.86% of 8k)
==========================================================================

Showing S3 (chunk 6 of 6): uity securities. In December 2024, we entered sold through a private placement to a select group of accredited investors 100,000,000 shares of common stock at a price of $0.85 per share and pre-funded warrants to purchase up to 76,452,000 shares of common stock at a purchase price of $0.8499 per pre-funded warrant, resulting in net proceeds of $143.0 million, after deducting offering expenses (the Private Placement). Additionally on August 2023, we filed with the SEC and the SEC declared effective, ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RAPT_OUT_39 [2025-04-29 08:00:36 -0400] 6995 Bytes | 1911 tokens | Cum: 8302 tkns (103.77% of 8k)
==========================================================================

This is our set of metrics for RAPT Therapeutics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 977,011 | Perf Month: -34.90% | Option/Short: Yes / Yes | Sales Y/Y TTM: -100.00% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 764.83K | Perf Quarter: -20.59% | Short Float: 5.82% | ROE: -77.09% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 1.28 | Index: RUT | Short Ratio: 5.23 | ROI: -67.65% |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 44.62 | Market Cap: 121.59M | Short Interest: 4.00M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.10 | Shs Outstand: 132.01M | Beta: -0.03 | EPS Surprise: -257.03% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: -2.02% | Shs Float: 68.80M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -16.24% | Inst Own: 45.18% | Sales past 5Y: -36.87% | Earnings: Mar 06 BMO |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -44.84% | Insider Own: 47.88% | Employees: 68 | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 17.79% | Insider Trans: 0.00% | Debt/Eq: 0.02 | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by RAPT Therapeutics officers or majority shareholders (if available).

Inside Trans: RAPT Therapeutics, Inc. (RAPT) by GRAY MARY ANN (Unknown Title) on 2025-03-31
- Director Stock Option (right to buy): 61202 shares at $1.0621 (D)

Inside Trans: RAPT Therapeutics, Inc. (RAPT) by Robbins Wendye (Unknown Title) on 2025-03-31
- Director Stock Option (right to buy): 49432 shares at $1.0621 (D)

Inside Trans: RAPT Therapeutics, Inc. (RAPT) by Wong Brian Russell (PRESIDENT AND CEO) on 2025-01-30
- Employee Stock Option (right to buy): 1746000 shares at $0 (D)

Inside Trans: RAPT Therapeutics, Inc. (RAPT) by Brockstedt Dirk G. (CHIEF SCIENTIFIC OFFICER) on 2025-01-30
- Employee Stock Option (right to buy): 515000 shares at $0 (D)

Inside Trans: RAPT Therapeutics, Inc. (RAPT) by Young Rodney KB (CHIEF FINANCIAL OFFICER) on 2025-01-30
- Employee Stock Option (right to buy): 642000 shares at $0 (D)

Inside Trans: RAPT Therapeutics, Inc. (RAPT) by HO WILLIAM (CHIEF MEDICAL OFFICER) on 2025-01-30
- Employee Stock Option (right to buy): 450000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -129865000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.9211
Average Volume: 820150.0
30-Day High: 1.22
30-Day Low: 0.782

[Detailed Financials: TTM 2024]
- Total Assets: $240,325,000.00
- Total Liabilities: $50,421,000.00
- Total Equity: $189,904,000.00
- Current Assets: $235,236,000.00
- Current Liabilities: $48,351,000.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-129,865,000.00
- Gross Profit: N/A
- Operating Income: $-136,101,000.00
- Earnings Per Share (EPS): -3.19

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $122,257,000.00

[Detailed Financials: FY 2024]
- Total Assets: $240,325,000.00
- Total Liabilities: $50,421,000.00
- Total Equity: $189,904,000.00
- Current Assets: $235,236,000.00
- Current Liabilities: $48,351,000.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-129,865,000.00
- Gross Profit: N/A
- Operating Income: $-136,101,000.00
- Earnings Per Share (EPS): -3.19

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $122,257,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of RAPT Therapeutics (RAPT).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about RAPT Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because RAPT is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for RAPT.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, RAPT could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect RAPT to increase 50% from its current price of $0.92, say: PRICE_TARGET[1.39]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of RAPT Therapeutics.

11) ETHICAL_RATING[]
Rate RAPT Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of RAPT Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

RAPT_IN_41 [2025-04-29 08:00:36 -0400] 126 Bytes | 29 tokens | Cum: 8533 tkns (106.66% of 8k)
==========================================================================

====================================
[2025-04-29 08:00:36] # Analysis Completed
Elapsed Time: 23.67 seconds